Web Analytics

3 Latest Announced Rounds

  • $3,500,000
    Seed

    1 Investors

    Technology, Information and Internet
    Dec 20th, 2024
  • $5,619,170
    Series B

    1 Investors

    Research Services
    Dec 20th, 2024
  • $8,000,000
    Unknown

    5 Investors

    Computer & Network Security
    Dec 20th, 2024
$671.88M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Gero

start up
United States - Palo Alto, California
  • 20/10/2023
  • Series A
  • $6,000,000

We are a preclinical stage AI drug discovery company with a mission to eliminate age-related diseases

We use AI to build clinically relevant disease phenotypes in real-world human data and identify diseases with shared biology. Then WES-enabled genetic study on these phenotypes allows us to discover novel targets applicable to several indications at once.

You can find our publications here: https://gero.ai/publications


Related People

Peter FedichevCo Founder

Peter Fedichev Singapore - Singapore

I'm an entrepreneur and scientist with over 20 years of experience in academic research and biotech business, co-founded three biotech companies: Quantum Pharmaceuticals, a drug discovery company, and Gero, a longevity startup and GlyNeura, a biotech-pharma company aiming to cure Neurodegenerative Diseases. My scientific background lies in the field of condensed matter physics, biophysics and bioinformatics. I've conducted research at Kurchatov Institute, one of the leading science government agencies in Russia, AMOLF, an academic institute for fundamental physics in the Netherlands, and the University of Innsbruck. I earned my M.S. in theoretical physics from the Moscow Institute of Physics and Technology and Ph.D. from the University of Amsterdam and currently have over 65 publications (h=28) in peer-reviewed journals. I believe that nothing beats the joy of discovery, the power of physics to uncover the laws of nature, and the challenge of aging research. My dream is to beat aging and experience life in space.